Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Jun 19:8:682.
doi: 10.3389/fbioe.2020.00682. eCollection 2020.

Nanotechnology in Chronic Pain Relief

Affiliations
Review

Nanotechnology in Chronic Pain Relief

Jing Chen et al. Front Bioeng Biotechnol. .

Abstract

Increasing awareness of chronic pain due to both injury and disease have encouraged drug companies and pharmaceutical researchers alike to design and fabricate better, more specific drugs for pain relief. However, overuse of clinically available pain medication has caused a multitude of negative repercussions, including drug tolerance, addiction, and other severe side effects, which can prolong suffering and reduce pain mediation. Applications of nanotechnology to the field of drug delivery has sought to enhance the treatment efficiency, lower side effects, and mitigate the formation of tolerance. The use of nanomaterials has several advantages for chronic pain relief, such as controlled release, prolonged circulation time, and limited side effects. With the development of nanotechnology, strategies for chronic pain relief have also bourgeoned utilizing a variety of nanomaterials and targeting surface modifications. In addition to using these materials as carriers for drug delivery, nanomaterials can also be designed to have inherent properties that relieve chronic pain. This minireview covers the current status of designed nanomaterials for pain relief and provides a discussion of future considerations for nanotechnology designed for relieving chronic pain.

Keywords: chronic pain; drugs; inflammation; nanotechnology; targeting.

PubMed Disclaimer

Figures

FIGURE 1
FIGURE 1
Current main strategies on chronic pain relief using nanotechnology including the delivery of drugs using nanocarriers, active targeting nanocarriers and ROS clearance via nanomaterials.
FIGURE 2
FIGURE 2
Future outlooks that can be taken up by using nanotechnology for chronic pain relief.

References

    1. Ambrose K. R., Golightly Y. M. (2015). Physical exercise as non-pharmacological treatment of chronic pain: why and when. Best Pract. Res. Clin. Rheumatol. 29 120–130. 10.1016/j.berh.2015.04.022 - DOI - PMC - PubMed
    1. Ballantyne J. C., Sullivan M. D. (2015). Intensity of chronic pain—the wrong metric. N. Engl. J. Med. 373 2098–2099. 10.1056/nejmp1507136 - DOI - PubMed
    1. Barenholz Y. C. (2012). Doxil® —the first FDA-approved nano-drug: lessons learned. J. Control. Release 160 117–134. 10.1016/j.jconrel.2012.03.020 - DOI - PubMed
    1. Binder A. I. (2007). Cervical spondylosis and neck pain. BMJ 334 527–531. 10.1136/bmj.39127.608299.80 - DOI - PMC - PubMed
    1. Blanco E., Shen H., Ferrari M. (2015). Principles of nanoparticle design for overcoming biological barriers to drug delivery. Nat. Biotechnol. 33:941. 10.1038/nbt.3330 - DOI - PMC - PubMed

LinkOut - more resources